메뉴 건너뛰기




Volumn 12, Issue 10, 2014, Pages 1417-1425

Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PREDNISONE; SIPULEUCEL T; ANDROSTANE DERIVATIVE; TISSUE EXTRACT;

EID: 84908693409     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0139     Document Type: Article
Times cited : (27)

References (41)
  • 1
    • 84908689124 scopus 로고    scopus 로고
    • Accessed July 1, 2013
    • American Cancer Society. Leading New Cancer Cases and Deaths-2013 Estimates. Available at: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfgures2013/index. Accessed July 1, 2013.
    • Leading New Cancer Cases and Deaths-2013 Estimates
  • 3
    • 80054690379 scopus 로고    scopus 로고
    • Characterising the castration-resistant prostate cancer population: A systematic review
    • Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65:1180-1192.
    • (2011) Int J Clin Pract , vol.65 , pp. 1180-1192
    • Kirby, M.1    Hirst, C.2    Crawford, E.D.3
  • 4
    • 84872078210 scopus 로고    scopus 로고
    • Abiraterone in metastatic prostate cancer without previous chemotherapy
    • Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-148.
    • (2013) N Engl J Med , vol.368 , pp. 138-148
    • Ryan, C.J.1    Smith, M.R.2    De Bono, J.S.3
  • 5
    • 77955066199 scopus 로고    scopus 로고
    • Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    • Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422.
    • (2010) N Engl J Med , vol.363 , pp. 411-422
    • Kantoff, P.W.1    Higano, C.S.2    Shore, N.D.3
  • 7
    • 84863323889 scopus 로고    scopus 로고
    • Horsham PA: Centocor Ortho Biotech
    • Zytiga [package insert]. Horsham, PA: Centocor Ortho Biotech; 2011.
    • (2011) Zytiga [Package Insert]
  • 8
    • 79959282824 scopus 로고    scopus 로고
    • Translating scientifc advancement into clinical beneft for castration-resistant prostate cancer patients
    • Attard G, de Bono JS. Translating scientifc advancement into clinical beneft for castration-resistant prostate cancer patients. Clin Cancer Res 2011;17:3867-3875.
    • (2011) Clin Cancer Res , vol.17 , pp. 3867-3875
    • Attard, G.1    De Bono, J.S.2
  • 9
    • 79957443342 scopus 로고    scopus 로고
    • Abiraterone and increased survival in metastatic prostate cancer
    • de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
    • (2011) N Engl J Med , vol.364 , pp. 1995-2005
    • De Bono, J.S.1    Logothetis, C.J.2    Molina, A.3
  • 10
    • 84908673797 scopus 로고    scopus 로고
    • Seattle WA : Dendreon Corporation; June
    • Provenge [package insert]. Seattle, WA : Dendreon Corporation; June 2011.
    • (2011) Provenge [Package Insert]
  • 11
    • 84878089792 scopus 로고    scopus 로고
    • Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: A cost-effectiveness analysis
    • Zhong L, Pon V, Srinivas S, et al. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis. PLoS One 2013;8:e64275.
    • (2013) PLoS One , vol.8 , pp. e64275
    • Zhong, L.1    Pon, V.2    Srinivas, S.3
  • 12
    • 84893650152 scopus 로고    scopus 로고
    • Abiraterone for Castration-Resistant Metastatic Prostate Cancer Previously Treated with a Docetaxel-Containing Regimen
    • Accessed July 1, 2013
    • National Institute for Health and Clinical Excellence. Abiraterone for Castration-Resistant Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen. NICE Technology Appraisal Guidance, 2012. Available at: guidance.nice.org.uk/ta259. Accessed July 1, 2013.
    • (2012) NICE Technology Appraisal Guidance
  • 13
    • 84908681576 scopus 로고    scopus 로고
    • Prostate Cancer (Metastatic, Hormone Relapsed)-Sipuleucel-T (1st Line) [ID573]
    • Accessed August 1, 2013
    • National Institute for Health and Care Excellence. Prostate Cancer (Metastatic, Hormone Relapsed)-Sipuleucel-T (1st Line) [ID573]. NICE Technology Appraisal Guidance. Available at: http://guidance.nice.org.uk/TA/WaveR/156#keydocs. Accessed August 1, 2013.
    • NICE Technology Appraisal Guidance
  • 14
    • 84857397717 scopus 로고    scopus 로고
    • Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer
    • Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012;104:273-279.
    • (2012) J Natl Cancer Inst , vol.104 , pp. 273-279
    • Huber, M.L.1    Haynes, L.2    Parker, C.3    Iversen, P.4
  • 15
    • 78650809219 scopus 로고    scopus 로고
    • Accessed July 1, 2013
    • Cleeland CS. Brief Pain Inventory User Guide. Available at: http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/BPI-UserGuide.pdf. Accessed July 1, 2013.
    • Brief Pain Inventory User Guide
    • Cleeland, C.S.1
  • 16
    • 0020396015 scopus 로고
    • Toxicity and response criteria of the Eastern Cooperative Oncology Group
    • Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
    • (1982) Am J Clin Oncol , vol.5 , pp. 649-655
    • Oken, M.M.1    Creech, R.H.2    Tormey, D.C.3
  • 17
    • 0020357091 scopus 로고
    • A convenient approximation of life expectancy (the "dEALE"). I. Validation of the method
    • Beck JR, Kassirer J P, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 1982;73:889-897.
    • (1982) Am J Med , vol.73 , pp. 889-897
    • Beck, J.R.1    Kassirer, J.P.2    Pauker, S.G.3
  • 18
    • 67651123901 scopus 로고    scopus 로고
    • Accessed August 1, 2013
    • Social Security Administration. Period Life Table, 2010. Available at: http://www.ssa.gov/OACT/STATS/table4c6.html#ss. Accessed August 1, 2013.
    • (2010) Period Life Table
  • 19
    • 84908681575 scopus 로고    scopus 로고
    • Accessed September 13, 2014
    • US Department of Veterans Affairs. Veterans Affairs Federal Supply Schedule. Contract Catalog. Available at: http://www.va.gov/nac/index.cf m?action=search&template=Search-Pharmaceutical-Catalog. Accessed September 13, 2014.
    • Veterans Affairs Federal Supply Schedule. Contract Catalog
  • 20
    • 84871332039 scopus 로고    scopus 로고
    • Fourth Edition. Available at Accessed June 1, 2013
    • Centers for Medicare and Medicaid Services (CMS). Current Procedural Terminology, Fourth Edition. Available at: http://www.cms.gov/apps/physician-fee-schedule/. Accessed June 1, 2013.
    • Current Procedural Terminology
  • 21
    • 0035397976 scopus 로고    scopus 로고
    • Estimating the cost of informal caregiving for elderly patients with cancer
    • Hayman JA, Langa KM, Kabeto MU, et al. Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol 2001;19:3219-3225.
    • (2001) J Clin Oncol , vol.19 , pp. 3219-3225
    • Hayman, J.A.1    Langa, K.M.2    Kabeto, M.U.3
  • 22
    • 44049089885 scopus 로고    scopus 로고
    • Bureau of Labor Statistics Web site Accessed June 1, 2013
    • United States Department of Labor. National Compensation Survey: Employer Cost for Employee Compensation. Bureau of Labor Statistics Web site. Available at: http://www.bls.gov/ncs/data.htm. Accessed June 1, 2013.
    • National Compensation Survey: Employer Cost for Employee Compensation
  • 23
    • 84908674328 scopus 로고    scopus 로고
    • Accessed July 1, 2013
    • Centers for Medicare and Medicaid Services (CMS). Medicare Fee For Service Payment-Acute Inpatient PPS. Available at: http://www.cms. gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Acute-Inpatient-Files-for-Download-Items/FY2013-FinalRule-CorrectionNotice-Files.html?DLPage=1&DLSort=1&DLSortDir=descen ding. Accessed July 1, 2013.
    • Medicare Fee for Service Payment-Acute Inpatient PPS
  • 24
    • 84874903258 scopus 로고    scopus 로고
    • Long-term costs of ischemic stroke and major bleeding events among Medicare patients with nonvalvular atrial fbrillation
    • Mercaldi CJ, Siu K, Sander SD, et al. Long-term costs of ischemic stroke and major bleeding events among Medicare patients with nonvalvular atrial fbrillation. Cardiol Res Pract 2012;2012:645469.
    • (2012) Cardiol Res Pract , vol.2012 , pp. 645469
    • Mercaldi, C.J.1    Siu, K.2    Sander, S.D.3
  • 25
    • 33846954758 scopus 로고    scopus 로고
    • Aspirin for the primary prevention of cardiovascular disease in women: A cost-utility analysis
    • Pignone M, Earnshaw S, Pletcher MJ, et al. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med 2007;167:290-295.
    • (2007) Arch Intern Med , vol.167 , pp. 290-295
    • Pignone, M.1    Earnshaw, S.2    Pletcher, M.J.3
  • 26
    • 33846251498 scopus 로고    scopus 로고
    • Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study
    • Liao L, Anstrom KJ, Gottdiener JS, et al. Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study. Am Heart J 2007;153:245-252.
    • (2007) Am Heart J , vol.153 , pp. 245-252
    • Liao, L.1    Anstrom, K.J.2    Gottdiener, J.S.3
  • 27
    • 84869781090 scopus 로고    scopus 로고
    • One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel
    • Burton TM, Lacey M, Liu F, et al. One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel. J Med Econ 2012;15:1217-1225.
    • (2012) J Med Econ , vol.15 , pp. 1217-1225
    • Burton, T.M.1    Lacey, M.2    Liu, F.3
  • 28
    • 84865249876 scopus 로고    scopus 로고
    • Healthcare resource use in advanced prostate cancer patients treated with docetaxel
    • Mehra M, Wu Y, Dhawan R. Healthcare resource use in advanced prostate cancer patients treated with docetaxel. J Med Econ 2012;15:836-843.
    • (2012) J Med Econ , vol.15 , pp. 836-843
    • Mehra, M.1    Wu, Y.2    Dhawan, R.3
  • 31
    • 34249034665 scopus 로고    scopus 로고
    • A review and meta-analysis of prostate cancer utilities
    • Bremner KE, Chong CA, Tomlinson G, et al. A review and meta-analysis of prostate cancer utilities. Med Decis Making 2007;27:288-298.
    • (2007) Med Decis Making , vol.27 , pp. 288-298
    • Bremner, K.E.1    Chong, C.A.2    Tomlinson, G.3
  • 32
    • 1942467444 scopus 로고    scopus 로고
    • Preferences of husbands and wives for outcomes of prostate cancer screening and treatment
    • Volk RJ, Cantor SB, Cass AR, et al. Preferences of husbands and wives for outcomes of prostate cancer screening and treatment. J Gen Intern Med 2004;19:339-348.
    • (2004) J Gen Intern Med , vol.19 , pp. 339-348
    • Volk, R.J.1    Cantor, S.B.2    Cass, A.R.3
  • 33
    • 0030841253 scopus 로고    scopus 로고
    • A comparison of perspectives on prostate cancer: Analysis of utility assessments of patients and physicians
    • Bennett CL, Chapman G, Elstein AS, et al. A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians. Eur Urol 1997;32(Suppl 3):86-88.
    • (1997) Eur Urol , vol.32 , pp. 86-88
    • Bennett, C.L.1    Chapman, G.2    Elstein, A.S.3
  • 34
    • 84908681574 scopus 로고    scopus 로고
    • Cost-utility analysis of enzalutamide versus abiraterone for the treatment of docetaxel refractory metastatic castrate resistant prostate cancer
    • Presented at the May 18-22 New Orleans, Louisiana. Poster PCN86
    • Yeung K, Gong CL. Cost-utility analysis of enzalutamide versus abiraterone for the treatment of docetaxel refractory metastatic castrate resistant prostate cancer. Presented at the 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 18-22, 2013; New Orleans, Louisiana. Poster PCN86.
    • (2013) 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • Yeung, K.1    Gong, C.L.2
  • 35
    • 84908681573 scopus 로고    scopus 로고
    • Cost-Effectiveness Thresholds
    • Accessed August 1, 2013
    • World Health Organization. Cost-Effectiveness Thresholds. CHOosing Interventions that are Cost-Effective (WHO-CHOICE). Available at: http://www.who.int/choice/costs/CER-thresholds/en/. Accessed August 1, 2013.
    • CHOosing Interventions That Are Cost-Effective (WHO-CHOICE)
  • 36
    • 0031900689 scopus 로고    scopus 로고
    • Net health benefts: A new framework for the analysis of uncertainty in cost-effectiveness analyses
    • Stinnett AA, Mullahy J. Net health benefts: a new framework for the analysis of uncertainty in cost-effectiveness analyses. Med Decis Making 1998;18:S68-80.
    • (1998) Med Decis Making , vol.18 , pp. S68-80
    • Stinnett, A.A.1    Mullahy, J.2
  • 37
    • 85038645694 scopus 로고    scopus 로고
    • Using net benefts to report cost-effectiveness results
    • Presented at the Accessed August 1, 2013
    • O'Day K, Globe D. Using net benefts to report cost-effectiveness results. Presented at the ISPOR Annual European Congress; November 5-8, 2011. Available at: http://www.ispor.org/congresses/Spain1111/presentations/W30-Globe-Oday.pdf. Accessed August 1, 2013.
    • (2011) ISPOR Annual European Congress; November 5-8
    • O'Day, K.1    Globe, D.2
  • 38
    • 10844271622 scopus 로고    scopus 로고
    • Study of hormone refractory prostate cancer: Hospital care and palliative care resource use at a VA medical center
    • Hwang SS, Chang VT, Alejandro Y, Mulaparthi S, et al. Study of hormone refractory prostate cancer: hospital care and palliative care resource use at a VA medical center. Cancer Invest 2004;22:849-857.
    • (2004) Cancer Invest , vol.22 , pp. 849-857
    • Hwang, S.S.1    Chang, V.T.2    Alejandro, Y.3    Mulaparthi, S.4
  • 39
    • 84878601468 scopus 로고    scopus 로고
    • Lower baseline prostate-specifc antigen is associated with a greater overall survival beneft from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial
    • Schellhammer P F, Chodak G, Whitmore JB, et al. Lower baseline prostate-specifc antigen is associated with a greater overall survival beneft from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 2013;81:1297-1302.
    • (2013) Urology , vol.81 , pp. 1297-1302
    • Schellhammer, P.F.1    Chodak, G.2    Whitmore, J.B.3
  • 41
    • 32944472716 scopus 로고    scopus 로고
    • Do oncologists believe new cancer drugs offer good value?
    • Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90-95.
    • (2006) Oncologist , vol.11 , pp. 90-95
    • Nadler, E.1    Eckert, B.2    Neumann, P.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.